AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06793319 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational app
Description: State Anxiety Inventory was filled out before the training. Atrial Fibrillation training was provided. After the training, the Situationality Anxiety Inventory was filled out again. It was aimed to evaluate the effect of education on anxiety.
Study NCT06795542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbosacral transforaminal epidural injection at the level of L4-5, L5-S1, or S1 neural foramina
Description: The most widely used injection therapy is epidural injection of steroids, by either the interlaminar route or the caudal route. More contentious are transforaminal injections of steroids. These involve the injection of steroids directly and accurately onto the affected spinal nerve, under radiologic guidance. Meanwhile, transforaminal injection of steroids has been shown to be more effective than interlaminar injection of steroids
Study NCT06795984 — intervention group
Intervention type: OTHER
Intervention: Establishing the correlation between KIR AA and KIR non-AA and CD56 endometrial cells and IVF succes
Description: The analysis aimed to compare CD56 levels between patients with the KIR AA genotype and those without. A multiple linear regression model was used to determine the predictive value of CD56+ levels, KIR genotype, and age on the number of blastocysts.
Study NCT06796803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab combined with apatinib and HAIC
Description: systemic therapy combined with locoregional theraphy as conversion therapy
Study NCT06796803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: camerlizumab+apatinib
Description: systemic therapy
Study NCT06795399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-131461
Description: OPC-131461 will be administered as oral tablets.
Study NCT06795399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: OPC-131461 matched placebo will be administered as oral tablets.
Study NCT06796270 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: The patients with nasopharyngeal carcinoma were given the dose of large segmentation radiotherapy, 2.64Gy/ time, 5 times/week, a total of 25 times, a total of 66Gy/5 weeks.
Study NCT06796842 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ballistic Exercises
Description: Ballistic training program was set for 6 weeks. Each week consisting of 5 exercises with sets of 3 and repetitions of 10,15 and 20 times, recovery time and training intensity differed each week.
Study NCT06796842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric exercises
Description: Plyometric training program was set for 6 weeks. With four exercises in 1st week. Five in 2nd and 3rd weeks, six exercises in 4th and seven exercises in last two weeks. Each exercise consisted of 3 sets with 10, 15 and 20 repetitions in each. Recovery time and training intensity differed each week.
Study NCT06795347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online VIPP-SD
Description: The Video-feedback Intervention to promote Positive Parenting and Sensitive Discipline is delivered online in this study. VIPP-SD is a manualized parenting intervention. The online version consists of 12 individual sessions, where the first and hereafter every second session consists of video recordings of mother and child in pre-defined everyday situations. The recordings are reviewed and discussed with the mother/parents during subsequent video-feedback sessions, where positive sequences in the interaction are pointed out by the intervener and form the basis of a discussion of pre-defined themes regarding child signals, attachment, child development, limit setting and sensitive parenting. The 12 sessions are conducted within five months from randomization with weekly or bi-weekly intervals.
Study NCT06795347 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Care As Usual
Description: Care As Usual is defined as any kind of help and support the parents may receive related to the socio-emotional development and mental wellbeing of their child in the municipality or the mental health services.
Study NCT06796244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Croq'Santé nutrition education program
Description: The Croq'Santé program aims to develop food literacy in children aged 8 to 11 years. It is based on the creation or adaptation of a recipe chosen by the children. The program is designed to run over the course of one school year, with approximately ten sessions. These sessions are delivered in schools by teachers, following a 3-hour training course. Teachers receive an intervention kit that includes a guide for conducting the different sessions, food images, and a mascot, which children can accessorize as they complete sessions and challenges. The sessions are organized around four stages: discover, invent, cook, and taste. Challenges are to be completed at the end of each stage with the child's family. At the end of the program, children are invited to cook and taste their recipe in a dedicated environment.
Study NCT05134779 — intervention group
Intervention type: PROCEDURE
Intervention: Live Biobank
Description: Tumor tissue will be collected from consented patients at sequential inflection points in the disease course: at the time of initial diagnosis, at the time of surgery and during recurrence or metastasis. In addition to this, 40ml of research bloods will also be collected at these key inflection points.
Study NCT06793059 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SHIELD
Description: Pipeline SHIELD device under study
Study NCT06793670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Landiolol
Description: Intravenous infusion of landiolol
Study NCT06793670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of saline solution of NaCl 0.9%
Study NCT06793371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
Description: CK-4021586 administered orally
Study NCT06793371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match CK-4021586
Description: Placebo administered orally
Study NCT06163950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigability assessment
Description: An isometric dynamometer will be used to assess fatigability development during a task to failure. Throughout the task, which consists of blocks of 3 minutes, neuromuscular assessments will take place to determine the evolution of fatigability and its peripheral and central determinants.
Study NCT05987605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1A46 Drug Substance
Description: Cycle 1 which will consist of an initial dose given on C1D1 and an intermediate dose given on C1D8, followed by a maintenance dose beginning on C1D15 and continuing while the patient is treated at that dose level
Study NCT06787677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF
Description: After the puncture needle reached the sphenopalatine ganglion (SPG), patients in the PRF group received PRF treatment in automatic mode for 360 s, at a maximum of 42°C, pulse frequency of 2 Hz, and pulse width of 20 ms.
Study NCT06787677 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NB
Description: After the puncture needle reached the sphenopalatine ganglion (SPG), patients in the NB group received nerve block with a mixture of 40 mg of triamcinolone and 2 ml of 0.75% bupivacaine with 2 ml of normal saline and 1:100000 epinephrine.
Study NCT04063501 — intervention group
Intervention type: OTHER
Intervention: Bronchoscopy
Description: The patient will then return within a week for a research bronchoscopy to sample the upper and lower airways
Study NCT04063501 — intervention group
Intervention type: OTHER
Intervention: Research Procedures
Description: electrocardiogram, blood work (CBC, chemistry, coagulation profile and liver function tests, pregnancy test if applicable), X-ray and pulmonary function (spirometry) testing, and provide the patient with a stool collection kit.
Study NCT06793085 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of interleukin-6 (il-6) concentration in blood serum
Description: Measurement of fasting interleukin-6 (il-6) concentration in fasting venous blood serum
Study NCT06793085 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of fasting tumor necrosis factor α (TNF-α) concentration
Description: Measurement of fasting tumor necrosis factor α concentration in fasting venous blood serum
Study NCT06793085 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of interleukin-18 (il-18) concentration
Description: Measurement of interleukin-18 (il-18) concentration in fasting venous blood serum
Study NCT06793085 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of interleukin-4 (il-4) concentration
Description: Measurement of interleukin-4 (il-4) concentration in fasting venous blood plasma
Study NCT06795971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure
Description: 1. Patients were placed at a 45-degree supine position, and noninvasive ventilation was delivered to the patient through a face mask connected to an ICU ventilator.~2. PEEP was started at 5 cm H2O with a FiO2 of 0.5 at initiation. PEEP and FiO2 were titrated to maintain SpO2 between 94 and 98%, remaining constant for at least 5 min.~3. CPAP was initiated with a first session of at least 4 h, the minimally required duration of noninvasive ventilation was 16 hours per day for at least 2 calendar days. Between noninvasive-ventilation sessions, patients received HFNO.
Study NCT06795971 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flow nasal oxygen
Description: 1. Oxygen was passed through a heated humidifier (MR850, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs, with a gas flow rate of 50 liters per minute and an FiO2 of 0.5 at initiation. HFNO heating temperature was prespecified at 37°C.~2. FiO2 will be titrated to maintain SpO2 between 94 and 98%, remaining constant for at least 5 min.~3. HFNO was applied for at least 2 calendar days.
Study NCT06795971 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilation
Description: 1. Patients were placed at a 45-degree supine position, and noninvasive ventilation was also delivered to the patient through a face mask connected to an ICU ventilator. The mask most appropriate for the patient will be selected and adjusted to minimize leakage and pressure points.~2. The inspiratory positive airway pressure (pressure support plus PEEP) was initiated between 12 and 14 cm H2O, PEEP was started at 5 cm H2O with a FiO2 of 0.5 at initiation. FiO2 was titrated to maintain SpO2 between 94 and 98%, remaining constant for at least 5 min.~3. NIV was initiated with a first session of at least 4 h, the minimally required duration of noninvasive ventilation was 16 hours per day for at least 2 calendar days. Between noninvasive-ventilation sessions, patients received HFNO.
Study NCT05646862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Participants will be administered a 9 milligram (mg) inavolisib tablet orally once a day (PO QD) on Days 1-28 of each 28-day cycle.
Study NCT05646862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle.
Study NCT05646862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle.
Study NCT05646862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpelisib
Description: Alpelisib will be administered to participants at the approved dose in combination with fulvestrant: 300 mg taken PO QD and on days 1-28 of each 28-day cycle.
Study NCT06629220 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tools
Description: In the co-creation meetings, developed tools will be presented. Participants will be asked to provide feedback and input to tailor these tools to the needs and preferences of men with suicidal thoughts/behavior.
Study NCT06628622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356225
Description: BI 1356225
Study NCT06628622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06628570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HRA + Biopsy
Description: High-Resolution Anoscopy, or HRA, is a standard of care procedure for screening and detection of premalignant lesions of the anus. Using a small, thin round tube called an anoscope, the anal canal is examined with a high-resolution magnifying instrument called a colposcope. The application of a mildly acidic liquid on the anal canal facilitates the evaluation of abnormal tissue such as anal dysplasia. Biopsies for histological confirmation of disease will be taken. Biopsies' reporting will follow the terminology, criteria, and recommendations of the Lower Anogenital Squamous Terminology (LAST) project. Histology results will be reported as benign, condyloma acuminatum, AIN grades 1-3, or cancer. For the proposed project, aHSIL+ will be defined as AIN2 (p16 block-positive), AIN3, and cancer at the HRA encounter. All other cases will be classified as \<aHSIL, including benign, condyloma acuminatum, and AIN1
Study NCT06628570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Anal Cytology
Description: Anal cytology collection (swab samples) will be performed as part of the standard of care during this study. The collected cells, suspended in the SurePath liquid-based medium, will be placed on a slide and microscopically examined by a board-certified pathologist. The sample will then be interpreted using the Bethesda System: negative for intraepithelial lesion or malignancy (NILM), ASCUS, LSIL, ASC-H, or HSIL. Pathologists interpreting the anal cytology will be blinded from hrHPV testing and biopsy histology.
Study NCT06628570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Genotyping of anal hrHPV infection
Description: Samples of exfoliated cells from the anal canal will be collected with Dacron swabs. To identify the infecting HPV genotype, DNA will be extracted from swab samples collected with the MagNA Pure LC DNA Isolation Kit III and an LC MagNA Pure system (Roche Diagnostics GmbH, Mannheim, Germany), followed by HPV typing using the TypeSeq assay, a laboratory prepared high-throughput next-generation sequencing assay developed by NCI will be performed as described. The assay uses three sequential PCR steps resulting in barcoded L1 amplicons sequenced and submitted to a bioinformatics pipeline for typing. This TypeSeq assay qualitatively detects and identifies 51 HPV genotypes (HPV types 3, 6, 11, 13, 16, 18, 26, 28, 30, 31, 32, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 71, 72, 73, 74, 76, 81, 82, 83, 84, 85, 86, 87, 89, 90, 91, 97, and 114), including 14 high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68)
Study NCT06628570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CINtec®PLUS
Description: Samples of exfoliated cells from the anal canal will be collected with Dacron swabs. Dual immunostaining with p16/Ki-67 will be performed on the residual cytologic specimen by Roche MTM Laboratories (Heidelberg, Germany), using the CINtec®PLUS Kit according to the manufacturer's instructions. The anal cytology material will be stained with a mouse monoclonal antibody directed against human p16INKa (p16) protein (clone E6H4) and recombinant rabbit monoclonal antibody directed against human Ki-67 protein (clone 274-11AC3V1), using the BenchMark ULTRA instrument (Ventana Roche). Samples with insufficient cellularity will be excluded from the evaluation. A trained cytotechnologist will review all cases for cells staining positively with both markers. A slide will be considered positive if 1 or more squamous epithelial cell(s) stained positive for both p16 and Ki-67 and dual stain-positive cells will be semi-quantitatively assessed (0, 1, 2-5, 6-50, >50).
Study NCT04472351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASCEND-I
Description: The intervention is an inpatient version of a novel behavioral intervention named ASCEND (A Strategy and Computer-based Intervention to ENhance Daily Cognitive Functioning after Stroke). ASCEND-I combines computer-based cognitive training exercises, with structured coaching sessions within patients' occupational therapy. Computer-based training is 30 minutes in length daily, and strategy training within patients' occupational therapy ranges from 30-60 minutes (depending on patients' clinical goals). The computer exercises aim to improve working memory (WM) through a series of engaging and interactive computer games (e.g., card games, virtual shopping, mental arithmetic). The Multicontext OT sessions aim to assist the participant in generalizing and transferring skills from the computer exercises to everyday activities and to develop further strategies to compensate for WM difficulties.
Study NCT04814420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delayed enhancement magnetic resonance imaging (DE-MRI)
Description: The patient will be injected with late gadolinium enhancement (0.01 mmol/kg standard dosage), which is a contrast agent used in clinical practice in MRI imaging studies. The contrast agent is used to enhance specific regions/tissues on MRI and, in this study, will allow the investigators to identify fibrotic tissue within the heart. The patient then undergoes the MRI sequence, which lasts approximately 20-25 minutes. Images will be reviewed for quality by trained technicians. This will be repeated after 6 months.
Study NCT04814420 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Delayed enhancement magnetic resonance imaging (DE-MRI)
Description: The patient will be injected with late gadolinium enhancement (0.01 mmol/kg standard dosage), which is a contrast agent used in clinical practice in MRI imaging studies. The contrast agent is used to enhance specific regions/tissues on MRI and, in this study, will allow the investigators to identify fibrotic tissue within the heart. The patient then undergoes the MRI sequence, which lasts approximately 20-25 minutes. Images will be reviewed for quality by trained technicians. This will be repeated after 6 months.
Study NCT04524247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physician Modified Endografts
Description: Modification procedure Description of modified device is detailed in Section 3.5 of IDE. In summary, the steps involved in modification of the Zenith Alpha thoracic stent grafts are;~1. Unsheathing of the stent graft~2. Retrieval of a trigger wire from the inner cannula of the delivery system~3. Rerouting of the trigger wire along the stent graft~4. Removal of proximal barbs.~5. Creation of fenestrations and/or branch cuffs~6. Placement of radiopaque markers around the fenestrations/ branch cuffs~7. Placement of temporary and/or permanent diameter constraining ties~8. (Optional) Placement of preloaded wires through the fenestrations/branch cuffs
Study NCT05379218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning
Description: Patients randomized to the RIC arm, cohorts of 4 consecutive patients will receive escalating therapy:~A. 4 consecutive patients will undergo 4 cycles of 3 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia B. Observing no safety events (see below) from patients in group A, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Day 1 of therapeutic hypothermia.~C. Observing no safety events from patients in group B, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1 and 2 of therapeutic hypothermia.~D. Observing no safety events from patients in group C, 4 consecutive patients will undergo 4 cycles of 5 minutes ischemia, followed by 5 minutes reperfusion, on Days 1, 2, and 3 of therapeutic hypothermia.~All infants will have an extra 1ml of blood collected.
Study NCT05566691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive thinking
Description: Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts.
Study NCT05607199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR103
Description: Twice Daily
Study NCT06294756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation of Sulfurous Thermal Water
Description: Active Inhalation protocol based on 12 consecutive sessions, 20 minutes each, once a day from Visit 1 through a conventional thermal water aerosolization Faset™system (Faset Spa, Trezzano sul Naviglio, Milan, Italy) delivering particles of TW with a diameter between 0.6 µm \<MMAD \< 5 µm. Treatment consisted of 10 minutes of warm steam and 10 minutes of aerosol inhalation with nasal prongs.
Study NCT06294756 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inhalation of Sterile Distilled non-pyrogenic Water
Description: Placebo Inhalation protocol based on 12 consecutive sessions, 20 minutes each, once a day from Visit 1 through a modified thermal water aerosolization Faset™system, previously disconnected from the hydraulic circuit that supplied TW and connected to non-pyrogenic sterile water reservoirs (Highly depurated water- Pharmaceutical grade FU-for external and internal use, Makeitlab, Canosa di Puglia, BT, Italy). Treatment consisted of 10 minutes of warm steam and 10 minutes of aerosol inhalation with nasal prongs delivering particles of SDW with a diameter between 0.6 µm \<MMAD \< 5 µm.
Study NCT05566691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive thinking + Mood induction
Description: Participants will be provided with information about how to cope with negative thoughts using positive thinking and asked to complete a worksheet walking them through the steps of positively reevaluating negative thoughts. They will be assigned to a positive mood induction before completion of the worksheet.